The brands include Atopiclair and Papulex.
Atopiclair, used to treat atopic dermatitis, has been launched in Hong Kong, Malaysia, Singapore and India, while Papulex, which is used to treat moderate acne, has been launched in Taiwan, India and Hong Kong.
By the end of the year, the company hopes to launch its products in four more countries.
Sinclair IS and Invida collaborated for the commercialisation of Sinclair’s dermatology brands in eleven Asia Pacific countries in December 2010.
Invida CEO John Graham said the collaboration would give Sinclair IS quick access and strong sales in the region without the need to invest significant resources that would be required to launch on their own.